Cart
sales@molnova.com
Cdc7 inhibitor
CAS No. 2206698-92-0
Cdc7 inhibitor( —— )
Catalog No. M13516 CAS No. 2206698-92-0
Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCdc7 inhibitor
-
NoteResearch use only, not for human use.
-
Brief DescriptionCdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.
-
DescriptionCdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2206698-92-0
-
Formula Weight323.756
-
Molecular FormulaC14H15ClFN5O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name5-chloro-6-(1,4-diazepan-1-yl)-2-(2-fluoropyridin-4-yl)pyrimidin-4(3H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. US Patent WO 2018055402.
molnova catalog
related products
-
SR-4835
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM Kd=98 nM; CDK13: Kd=4.9 nM) which disables triple-negative breast cancer (TNBC) cells.
-
CAN-508
CAN-508 is a potent, selective CDK9 inhibitor with IC50 of 0.35 uM (CDK9/cyclin T1), displays >35 fold selectivity over CDK1/2/4/7 (IC50=13.5-70 uM).
-
Purvalanol A
A potent, cell-permeable, selective inhibitor of CDK with IC50s of 4, 70, 35, 850, and 75 nM for cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D1 and Cdk5-p35, respectively.
